You are currently browsing the archives for 10 May 2016.
Displaying 1 entry.

The Genous stent is commercially available in more than 60 countries since 2005.

The Genous stent is commercially available in more than 60 countries since 2005, has been a safe, effective a safe, effective alternative to drug – eluting stents and data data from more than 5,000 patients sponsored enterprise clinical studies. There is a growing body of evidence from multiple clinical studies that. The Genous stent is effective for patients who do not respond or can not tolerate, is long-term dual antiplatelet therapy.

The study included 178 consecutive patients percutaneous coronary intervention percutaneous coronary intervention for de novo bifurcation lesion with a Genous stent and underwent 465 consecutive patients BMS BMS.. The cumulative rate of the primary endpoint, the composite of cardiac death, myocardial infarction or target lesion revascularization at one year follow-up was 12.4 percent for patients with a Genous stent BMS a 30 percent reduction to 17.2 percent in the control group were treated with BMS. The definite or probable stent thrombosis was 1.7 percent for the Genous stent patient group compared to 3.4 percent for the BMS treated patient group.